

Thursdays Webinars

EuroBleedNet

Hereditary Stomatocytosis

Immacolata Andolfo, PhD

University of Naples, Federico II CEINGE, advanced biothecnologies ERN-EuroBloodNet subnetwork: Red blood cell defects



Co-funded by the Health Programme of the European Union Naples – Italy September 24, 2020



 Network Hematological Diseases (ERN EuroBloodNet)



I have nothing to disclose



Network Hematological Diseases (ERN EuroBloodNet)







Network Hematological Diseases (ERN EuroBloodNet)



- Wide spectrum of inherited hemolytic disorders in which the red cell membrane cation permeability is increased (cation leak)
- The cation leak results in deregulation
 Stomatocyte
 of cellular volume, which leads to morphological abnormality of RBCs (stomatocytes,
 RBCs with a stoma across the center, at peripheral blood smear)
- The clinical presentation of HSt is highly variable: variable expressivity



Thursdays Webinars

Genetic and allelic heterogeneity



Network Hematological Diseases (ERN EuroBloodNet)







- Stomatin deficient cryohydrocytosis with mental retardation, seizures, hepatosplenomegaly (*GLUT1*)
- Phytosterolemia non-leaky stomatocytosis with macrothrombocytopenia (ABCG5; ABCG8)
- Dehydrated Hereditary Stomatocytosis (DHS1) with perinatal edema and/or pseudohyperkalemia (*PIEZO1*)

European Reference Network for rare or low prevalence complex diseases

> Network Hematological Diseases (ERN EuroBloodNet)

Andolfo et al. AJH 2017







Reference Network for rare or low prevalence complex diseases

Hematological

Diseases (ERN EuroBloodNet)

It is a rare form of stomatocytosis associated with a **cold-induced cation leak**, **hemolytic anemia**, **hepatosplenomegaly**, **cataracts**, **seizures**, **mental retardation**, and **movement disorder**.

It is caused by mutations in *SLC2A1 gene*, that codifies for the **GLUT1** transporter (associated with both loss of glucose transport and a cation leak). Autosomal recessive inheritance.

Andolfo et al. AJH 2017

Syndromic HSt: Phytosterolemia

- It is characterized by lipid metabolic disorder,
 stomatocytic hemolysis, and macrothrombocytopenia.
- They showed normal erythrocyte cation content.
- The causative genes are: *ABCG5* and *ABCG8*, that codify for two ATP-cassette transporters that mediate efflux of dietary sterols from the small intestine. Autosomal recessive inheritance (ABCG5/ABCG5; ABCG8/ABCG8; ABCG5/ABCG8).
- Incorporation of sterols into RBCs and platelets results in abnormal morphology and function.

Patient		Age, years	Serum, µmol/L		
	Sex		Stigmasterol	Cholestanol	Sitosterol
A-II-2	F	34	409.0	99.8	1103.4
B-II-I	F	43	209.8	102.9	716.9
C-II-I	М	62	118.5	94.9	348.4
C-II-2	М	60	344.3	329.0	776.9
C-II-3	М	57	273.1	138.6	725.8
C-II-4	F	55	449.5	246.7	1195.3
Controls $(n = 15)^a$			13.0 ± 5.1^{a}	$25.3~\pm~8.8^a$	28.3 ± 8.2^{a}

Table 2. Serum Sterols Levels of Phytosterolemia Patients in 3 Families



Hematological Diseases (ERN EuroBloodNet) Andolfo et al. AJH 2017

uropean eference

complex diseases

ify Small Intestine

A-11-2







Non-syndromic

•Overhydrated Hereditary Stomatocytosis (OHS) (**RHAG**) Cryohydrocytosis (**Band 3**) Familial Pseudohyperkalemia (FP) (**ABCB6**) Dehydrated Hereditary Stomatocytosis (DHS1/DHS2) (**PIEZO1**; **KCNN4**)



 Network Hematological Diseases (ERN EuroBloodNet)

Andolfo et al. AJH 2017



Non-Syndromic HSt: Overhydrated Hereditary Stomatocytosis





- OHS is characterized by anemia of a variable degree with macrocytosis, low MCHC, and a right shift of the osmolarity curve at ektacytometric analysis
- ✓ It is characterized by an increase in the monovalent cation leak also associated with the absence of stomatin
- It is caused by mutations in the ammonium transporter RHAG (autosomal dominant inheritance)



Thursdays Webinars



Hematological Diseases (ERN EuroBloodNet)

At peripheral blood smear we can observe more than 20%
 of stomatocytes

Iolascon A, Andolfo I, Russo R. BJH 2019; Andolfo et a. AJH 2017; Andolfo et al, AJH 2013





- ✓ Cryohydrocytosis is characterized by increased permeability to Na+/K+ cations at low temperatures (0−4°C).
- ✓ It is a mild hemolytic anemia due to a minimal cation leak.
- Its pathophysiology has been linked to missense mutations in the SLC4A1 gene that encodes the band 3 protein.



Hematological Diseases (ERN EuroBloodNet) These substitutions convert band 3 from an anion exchanger into a cation channel, which is a pathogenic mechanism entirely different from the loss-of-function mechanism that causes hereditary spherocytosis.

Iolascon A, Andolfo I, Russo R. BJH 2019; Andolfo et a. AJH 2017; Andolfo et al, AJH 2013

Non-Syndromic HSt: Familial Pseudohyperkalemia



- Dominantly inherited genetic trait
- Characterized by a temperature-dependent, in vitro, loss of K⁺ cation from red cells
- Plasma [K+] was increased when measured in blood stored at or below body temperature
- The patients show alterations in MCV
- ✓ Missense mutations in ABCB6 gene were identified in FP



• Network Hematological Diseases (ERN EuroBloodNet)

Iolascon A, Andolfo I, Russo R. BJH 2019; Andolfo et a. AJH 2017; Andolfo et al, AJH 2013

		ABCB6 patients FP
Number of patier	ts (%)	11 (15.1)
Gender (female/n	10 (90.9)/1 (9.1)	
Onset of sympton	$\begin{array}{c} 42.5 \pm 6.6 \\ (40.5; 8) \end{array}$	
Age of diagnosis	47.1 ± 5.6 (43.5; 8)	
Blood count		
	Ref range ^c	
RBC (10 ⁶ /µL)	3.9-5.6	$\substack{\textbf{3.6}\pm\textbf{0.4}\text{ (3.8;}\\\textbf{11)}}$
Hb (g/dL)	11.0-16.0	$\begin{array}{c} 13.5 \pm 0.4 \\ (13.1; 11) \end{array}$
Hct (%)	33.0-45.0	$\begin{array}{c} 42.6 \pm 1.3 \\ (42.0; 11) \end{array}$
MCV (fL)	70.0-91.0	$\begin{array}{c} 101.3 \pm 2.3 \\ (100.2; 11) \end{array}$
MCH (pg)	23.0-33.0	31.1 ± 0.6 (31.4; 11)
MCHC (g/dL)	23.0-33.0	$\begin{array}{c} 33.2 \pm 0.9 \\ (32.5; 11) \end{array}$
Retics count (x10 ³ /µl.)	-	140.3 ± 35.7 (140.3; 2)
Retics %	0.5-2.0	$\begin{array}{c} 2.9 \pm 1.2 \ \text{(2.9;} \\ 2 \text{)} \end{array}$



ABCB6 variants screening in blood donors population

_

- Variants in *ABCB6* gene are present in healthy subjects and in blood donor population
- Storage of FP blood causes a significant increase in blood K+ levels causing problems mostly in **pediatric/neonatal care**, indeed several cases of whole blood transfusion in infants leading to cardiac arrest and death have been described









Network Hematological Diseases (ERN EuroBloodNet)

Andolfo et al, Haematologica 2016

Syndromic/Non-Syndromic HSt: Dehydrated Hereditary Stomatocytosis





- ✓ Autosomal dominant hemolytic anemia associated with cation leak
- The two causative genes identified until now are *PIEZO1* and *KCNN4*
- It is a rare condition, but rather underdiagnosed. A recent study estimated an incidence of 1 case in 8000 adults.





Network Hematological Diseases (ERN EuroBloodNet)

Iolascon A, Andolfo I, Russo R. BJH 2019; Andolfo et a. AJH 2017, Andolfo et al, AJH 2018





Main characteristics			
Macrocytic anemia			
Hemolysis	Ret count ↑ LDH ↑ Hap ↓ Bil (tot, ind) ↑		
Splenomegaly and gallstones	Splenectomy is contraindicated due to increased risk of severe thromboembolic complications		
Variable numbers of stomatocytes at PB smear	<20%		
Pre-and/or perinatal edema (syndromic form). Pregnancy should be monitored	Perrel shakes		
Pseudohyperkalemia (syndromic form)	Kalemia		
Severe iron overload (hepatosiderosis)	Ferritin, transferrin saturation, and liver iron concentration		



 Network Hematological Diseases (ERN EuroBloodNet) Andolfo et al. AJH 2018; Picard et al., Haem. 2019; Andolfo et al. Haematologica 2016; Andolfo et al. Blood 2013

PIEZO1: physiological functions

- ✓ PIEZO1 is a mechanoreceptor (non-selective cation channel activated by several mechanical stimuli) that forms a trimeric propeller-like structure of about 900 kDa in the plasma membrane
- It plays an important physiological role in several biological processes such as regulation of urinary osmolarity, control of blood pressure, regulation of hydration and volume of erythrocytes, sensor of epithelial cell crowding and stretching, formation and development of blood and lymphatic vessels
- It is present only at a few hundred copies per RBC but functions as major determinant of the RBC hydration status



European Reference Network

for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet) Wu J et al Trends in Bioc Sci 2017; Alper SL. Curr Top Membr. 2017; Martins JR, et al. Pflugers Arch. 2016; Wang S, et al. J Clin Invest. 2016; Gudipaty SA, et al. Nature. 2017; Li J, et al. Nature. 2014; Ranade SS, et al. 2014; Andolfo et al. Blood. 2013.







Gain-of-function (GOF) mutations in PIEZO1

- Several electrophysiology studies demonstrated that the pathogenic variants cause a gain-offunction phenotype with delayed inactivation of the channel
- RBCs dehydration is due to an excessive potassium efflux and calcium influx, accompanied by further potassium efflux through the Gardos channel and osmotic efflux of water
- Other mechanisms of PIEZO1 dysfunction include altered response to osmotic stress and membrane trafficking (phenotype heterogeneity of the disease)



- **KCNN4** gene encodes for the Gardos channel (KCa3.1), the erythroid Ca²⁺-sensitive K⁺ channel
- The families described until now are few (recurrent mutations R356H, V282M and V282R)
- The mutated channel showed a higher activity when compared to the wild type channel demonstrating that the mutations are gain-of-function
- Is it the same disease? "Gardos channelopathy". There are differences in cellular pathophysiology and clinical presentation



Diseases (ERN EuroBloodNet)









DHS2 - KCNN4- Gardos DHS1 - PIEZO1 European Reference

Network for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet)



Two large cohort studies: 123 and 126 patients with HSt





Patients with PIEZO1	High-rank	Low-rank	D§
mutations	(n = 14)	(n = 15)	F °
Age at diagnosis (years)	$17.4 \pm 3.3 \; (17.5; 14)$	$24.9 \pm 6.5 \ (20.0; \ 11)$	0.39
Gender (Female/Male)	4 (28.6)/10 (71.4)	9 (60.0)/6 (40.0)	0.09
Hematological data			
Hb (g/dL)	11.4 ± 0.8 (11.3; 14)	$12.6 \pm 0.4 \; (12.2; 15)$	0.30
MCH (pg)	$35.0 \pm 1.5 \; (36.0; 13)$	$36.5 \pm 1.5 \; (36.0; 15)$	0.84
MCHC (g/dL)	36.7 ± 1.7 (34.8; 14)	$33.9 \pm 0.3 \ (33.7; \ 15)$	0.12
Retics abs count (x10 ³ /µL)	$181.3 \pm 34.4 \; (165.6; \; 13)$	$153.5 \pm 26.4 \ (139.3; \ 13)$	0.57
Laboratory data, iron balance,	and transfusion		
regimen			
Total bilirubin (mg/dL)	$4.4 \pm 0.7 \; (4.3; 14)$	2.5 ± 0.7 (1.5; 8)	0.06
LDH (U/L)	333.8 ± 51.0 (315.0; 11)	232.6 ± 18.2 (242.5; 8)	0.17
Ferritin (ng/mL)	720.9 ± 129.3 (626.0; 14)	196.7 ± 57.1 (182.5; 6)	0.02
Ferritin level/dosage age [‡]	$47.2 \pm 8.3 \; (38.4; 14)$	17.4 ± 3.7 (16.3; 6)	0.01







Andolfo et al, AJH 2018; Picard et al., Haem. 2019





Diagnosis and therapy of HSt



Network Hematological Diseases (ERN EuroBloodNet)



Diagnostic workflow of HSt

Network Hematological

Diseases (ERN EuroBloodNet)





Thursdays Webinars

Russo et al 2018; Andolfo et al, 2018; Zaninoni et al, 2018

Genetic testing of HSt in the NGS era



We obtained an overall diagnostic yield of 65% using our t-NGS panel

18% of patients with clinical suspicion of congenital dyserythropoietic anemias (CDAs), mainly CDAI and II, carried mutations in PIEZO1 gene.



for rare or low prevalence complex diseases

O Network Hematological Diseases (ERN EuroBloodNet) 9% of patients with clinical suspicion of hereditary spherocytosis (HS) carried mutations in

PIEZO1 gene

Differential diagnosis

- DHS is often misdiagnosed, at clinical level, as hereditary spherocytosis (HS) or congenital dyserythropoietic anemias (CDAI/II)
- In several cases DHS can also be misdiagnosed as hereditary hemochromatosis
- The genetic analysis is crucial also to avoid not useful treatments as for example splenectomy
- It is important to evaluate the possible co-inheritance of other genetic traits that could account for variability of the phenotype observed





Network Hematological Diseases (ERN EuroBloodNet) Hypercellular bone marrow with erythroid hyperplasia (mimicking myelodysplastic syndrome) in a patient with DHS Paessler M, Hartung H. Blood. 2015



Standard treatment and possible future therapy

- The first-line treatment is based only on supportive care: folates, Vit.B12, transfusions, iron chelation.
- ✓ Splenectomy is <u>contraindicated</u> (increased risk of thrombosis).
- SENICAPOC (ICA -17043) is a Gardos channel antagonist , previously proposed for use in sickle cell anemia, tested in phase 3 study
- SENICAPOC is efficient in preventing RBC K+ loss and dehydration in both *PIEZO1* and *KCNN4* mutated cells.
- Other possible treatments are the inhibitors of PIEZO1



Hematological Diseases (ERN EuroBloodNet)





Thursdays Webinars

Rapetti-Mauss R. et al., Haematologica 2016; Rivera A. et al., AJH 2017





Dehydrated hereditary stomatocytosis: role of *PIEZO1 in RBCs*



Network Hematological Diseases (ERN EuroBloodNet)

Constitutive Piezo1 GOF and blood-cell-specific PiezIo1 GOF transgenic mice (R2456H) showed:

- Stomatocytes at PB, reduced osmotic fragility, and splenomegaly \checkmark
- Mild anemia, with lower Hb level and increased ret. Number/MCV

Gain-of-function Piezo1 mice display hallmark clinical features observed in human DHS patients, including RBC dehydration, mild anemia, and splenomegaly.

 27.35 ± 0.10

 375.68 ± 13.54



wild type	GOF ^{blood}	heterozygous Piezo1GOF ^{blood}	
	wild type (n = 6)	Heterozygous Piezo1GOF ^{blood} (n = 5)	Homozygous Piezo1GOF ^{blood}
RBC (M/uL)	9.82 ± 0.35	9.98 ± 0.39	9.50 ± 0.37
HGB (a/dL)	14.90 ± 0.22	14.02 ± 0.16**	12.19 ± 0.34****
HCT (%)	56.27 ± 0.57	51.22 ± 1.09**	42.06 ± 1.25****
MCV (fL)	49.43 ± 0.12	51.08 ± 0.56*	54.64 ± 0.37****
MCH (pg)	14.12 ± 0.05	14.34 ± 0.02**	14.56 ± 0.07***

29.14 ± 0.15****

450.06 ± 7.03**



for rare or low prevalence complex diseases

MCHC (a/dL)

RET # (k/ul)

③ Network Hematological Diseases (ERN EuroBloodNet)

Shang Ma et al, Cell 2018

Thursdays Webinars

 $OF^{blood}(n = 7)$

541.29 ± 11.79****

 27.00 ± 0.59



Piezo1 GOF mutations attenuate Plasmodium infection





Shang Ma et al, Cell 2018

Network for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet)

③ Network

PIEZO1 activation delays erythroid differentiation and reticulocyte



maturation in DHS1



Network for rare or low prevalence complex diseases

Network Hematological

- ✓ PIEZO1-patients showed reduced reticulocyte count compared to other patients with anemias due to membrane defects. This suggested that PIEZO1-patients might suffer from delayed erythrocyte maturation.
- ✓ In vitro culture assay showed delay in erythroid differentiation of progenitor cells obtained from patients with PIEZO1 mutations through transcriptional regulation (STAT5-ERK1/2-NFAT-EPO). It is mutations dependent.
- Characterization of reticulocytes and erythrocytes from 10 DHS1 patients revealing alterations in deformability and vesicle content that implicate a maturational defect in DHS1.
- DHS1 patients show differences in the extent and rate of loss of CD71 and RNA content over time. So, overactivation of PIEZO1 impacts reticulocyte maturation.

Thursdays Webinars

Hematological Diseases (ERN EuroBloodNet) Andolfo et al, AJH 2018; Pedro L. Moura et al., 2020; Caulier et al., 2020

Hematological Diseases (ERN EuroBloodNet)





Hepatic iron overload in DHS1

- **Severe iron overload** with several cases of hepatosiderosis has been described for *PIEZO1* patients.
- Hepatic iron overload is independent from the degree of anemia, the transfusion regimen, and the splenectomy
- Ferritin and ferritin/age ratio is very high in DHS1. There is a poor correlation between ferritin levels and liver iron content.
- Most of the patients with a severe phenotype (mostly with impaired iron balance) carried mutations in the **pore domain**, while most of the patients with mild phenotype exhibited variations in the **non-pore domain**





		patients ^a DHS1	patients ^a DHS2
Number of patients (%)		36 (49.3)	5 (6.8)
Gender (female/male)		16 (44.4)/20 (55.6)	2 (40.0)/3 (60.0)
Onset of symptoms (years)		$7.7 \pm 2.0 \text{ (1.5;} \\ 18\text{)}$	9.4 \pm 6.2 (7.0; 3)
Age of diagnosis (years)		21.5 ± 3.2 (20.0; 27)	29.3 ± 11.8 (27.5; 4)
Ferritin (ng/mL)	22.0-275.0	563.7 ± 106.3 (425.5; 20)	302.0 ± 127.0 (291.0; 4)
Ferritin level/ dosage age ^b	-	40.1 ± 6.7 (30.3; 19)	11.4 ± 4.5 (11.3; 4)

for rare or low prevalence complex diseases

Hematological Diseases (ERN EuroBloodNet) Picard et al., Haematologica 2019 Andolfo et al., AJH, 2018 Andolfo et al., Haematologica, 2017

Thursdays Webinars

IZ CNINIA



Hepcidin and ERFE dosage in DHS1 patients



iron recycling (splenic macrophages)

Thursdays Webinars



Hepcidin expression is impaired in DHS1 patients by a mechanism only partial regulated by ERFE



Network Hematological Diseases (ERN EuroBloodNet)

Andolfo et al., AJH 2020

PIEZO1 in liver: physiological role



- Intracellular calcium concentration increases after PIEZO1 activation by Yoda-1 in primary \checkmark hepatocytes
- ✓ Activation of PIEZO1 by both Yoda-1 and GoF mutations cause Hamp suppression in hepatic cells

European Reference Vetwork for rare or low prevalence complex diseases

Hematological

③ Network

Inhibition of PIEZO1 by GsMTx-4 leads to the rescue of the phenotype

Thursdays Webinars

Diseases (ERN EuroBloodNet)

Andolfo et al. AJH 2020

Impaired BMP-SMADs pathway in PIEZO1-GOF mutants





HAMP gene expression is regulated by the BMP/SMADs pathway

PIEZO1 activations leads to ERK1/2 phosphorylation in other cells



PIEZO1 was activated by Yoda-1 (1.5µM)

Camaschella C. et al., Haematologica 2020

Diseases (ERN EuroBloodNet)



- PIEZO1 GOF mutants showed increased phosphorylation of ERK1/2 in hepatic cells and inhibition of BMP-SMADs pathway
- ✓ The inhibition of BMP/SMADs signaling was confirmed by the downregulation of the target genes: SMAD6/SMAD7/ID1/ID3

Andolfo et al., AJH 2020 Thursdays Webinars





HuH7 cells

✓ The inhibition of PIEZO1 by GsMTx-4 rescued the Hamp and ID1 gene expression.





✓ There is an inverse correlation between intracellular [Ca++] and *Hamp* expression and between pERK1/2 and pSMAD1/5/8.



Network Hematological Diseases (ERN EuroBloodNet)

Andolfo et al., AJH 2020

Model of pathogenic mechanism of DHS





European Reference Network for rare or low prevalence complex diseases

Network
 Hematological
 Diseases (ERN EuroBloodNet)

Andolfo et al, AJH 2017

Proposed model: PIEZO1 regulation of hepatic iron metabolism





Thursdays Webinars

Take home messages

- HSt are a wide spectrum of inherited hemolytic disorders in which the RBC membrane cation permeability is increased.
- DHS is the most frequent condition within this class of anemias. It is an autosomal dominant hemolytic anemia caused by GOF mutations in both *PIEZO1* and *KCNN4* genes.
- ✓ The diagnosis of Hst is very challenging because of the presence of overlapping phenotypes, variable expressivity, allelic and genetic heterogeneity. DHS is in differential diagnosis with HS and CDAs.
- ✓ GOF mutations in *PIEZO1* caused impaired erythroid differentiation and reticulocytes maturation.
- ✓ GOF mutations in *PIEZO1* cause decreased *Plasmodium* infection.
- ✓ Iron overload in DHS1 is directly caused by GOF mutations of *PIEZO1* at hepatic level by impairing of *Hamp* gene expression.



Diseases (ERN EuroBloodNet)

This finding opens a new field of study on *PIEZO1* and iron metabolism.





Acknowledgments

UOC Medical Genetics and Hereditary Anemias Research Lab University of Naples "Federico II" Ceinge, advanced biotechnologies



STOCKHOLM

23RD CONGRESS

JUNE 14-17 | 2018

European Hemaplogy Association



EHA Junior Research Grant 2018, 3978026



EUROPEAN HEMATOLOGY ASSOCIATION

Prof. Achille Iolascon Roberta Russo

Barbara Eleni Rosato Roberta Marra Francesco Manna Simone Della Monica

European Reference Network for rare or low prevalence complex diseases

> Network Hematological Diseases (ERN EuroBloodNet)

